삼진제약

005500KOSPI의약품 제조업

58.9 / 100

Reference Date: 2026-07-24

Financial Score25.5 / 40

News Sentiment18.4 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Revenue metrics are weak. Slightly down 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samjin Pharmaceutical operates a diverse portfolio spanning OTC drugs, specialty pharmaceuticals, and APIs, leveraging its competitive edge in the pharmaceutical market. The company focuses on developing innovative treatments for age-related diseases and metabolic disorders, with key products including the anticoagulant 'Plaeris' and analgesic 'Geborin'. It is expanding into health foods and medical devices, and has enhanced its global production capabilities through the 2022 completion of its Osong facility.

Number of Employees

819people

Average Salary

81.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.11Industry Average 11.235.0Point

In line with industry avg

PBR

0.82Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

8.76Industry Average 4.017.0Point

2.2x industry avg (excellent)

Debt Ratio

11.36Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 10.2% (improving, 3yr)

Detailed News Sentiment

30 totalPositive 21Neutral 8Negative 1Average Sentiment Score 73.5

Neutral
[바이오스냅] 동국제약, '마데카 선쉴드 패드' 출시
동국제약의 새로운 자외선 차단제 출시 소식은 관련 산업에 긍정적 영향을 미칠 수 있으나, 삼진제약의 직접적인 영향은 제한적입니다.
Positive
"항혈전제 임상 근거 공유"…삼진, 심포지엄 개최
삼진제약의 심혈관질환 예방 관련 임상 근거 공유 심포지엄 개최로 긍정적인 시장 반응 예상.
Positive
삼진제약 '플래리스', 아스피린 대비 심혈관 위험 14%↓…10년 장...
삼진제약의 플래리스가 아스피린 대비 심혈관 복합 사건 위험을 14% 감소시키는 효과를 보여 장기 추적 연구 결과 발표로 긍정적 평가를 받았다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 17,880Won52-week high 24,70052-week low 17,240

1-month return2.0Point

1m -2.83% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-21
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-09